Celgene and Agios entered a three-year global strategic collaboration to discover and develop therapies targeting cancer cell metabolism, including IDH1 and IDH2 mutant inhibitors. Agios received $130 million upfront (including an equity investment). Celgene gained exclusive options to license clinical candidates emerging from the collaboration after Phase I. Each optioned program carried up to $120 million in milestones plus royalties. This deal ultimately led to the development of ivosidenib (Tibsovo/IDH1 inhibitor) and enasidenib (Idhifa/IDH2 inhibitor). Rights were later restructured: Celgene retained worldwide enasidenib rights; Agios regained US ivosidenib rights in 2016 amendments, with Celgene keeping ex-US option.